Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer

Breast Cancer Research

Volumn 2, Issue 2, 2000, Pages 116-124

  Donovan, J ^a   Slingerland, J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Breast cancer; Cell cycle; Cyclin dependent kinase inhibitor; Human mammary epithelial cells; Transforming growth factor

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P19; PROTEIN P21; PROTEIN P27; PROTEIN P57; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CELL; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL TRANSFORMATION; CONTROLLED STUDY; EXTRACELLULAR SPACE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MITOGENICITY; MITOSIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL CYCLE; CYCLINS; FEMALE; GENES, MYC; GENES, RAS; HUMANS; PHOSPHORYLATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034469509     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr43     Document Type: Review

References (107)

1. Transforming growth factor-β
2. Transforming growth factor β and cell cycle regulation
3. TGF-β1-induced inhibition of mouse mammary ductal growth: Developmental specificity and characterization
4. Reversible inhibition of mammary gland growth by transforming growth factor-β
5. Transforming growth factor-β and breast cancer: Mammary gland development
6. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1
7. Mammary tumor suppression by transforming growth factor β1 transgene expression
8. Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models
9. Effects of the transforming growth factor β on growth of human mammary epithelial cells in culture
10. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis
11. TGF-β signal transduction
12. Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
13. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metatstatic cancer: Malignant melanoma as a paradigm
14. The transforming growth factor-β family
15. Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor-growth inhibitor in serum-free medium
16. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta
17. Transforming growth factor beta induces myoblast differentiation in the presence of mitogens
18. Type β transforming growth factor is the primary differentiation inducing serum factor for normal human bronchial epithelial cells
19. Regulation of proliferation and differentiation of respiratory tract epithelial cells by TGF-β
20. Principles of Cdk regulation
21. G1 phase progression: Cycling on cue
22. Inhibitors of mammalian G1 cyclin-dependent kinases
23. CDK inhibitors: Positive and negative regulators of G1-phase progression
24. Creative blocks: Cell cycle checkpoints and feedback controls
25. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
26. Transcriptional control by E2F
27. Regulation of CDKs by phosphorylation
28. Activation of the various cyclin/cdc2 proteins
29. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation
30. Cdc25 protein phosphatases in cell proliferation
31. Cyclin D1 as a cellular proto-oncogene
32. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells
33. A cell cycle regulated inhibitor of cyclin dependant kinases
34. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β
35. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
36. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
37. Regulation of the Cdk inhibitor p27 and its deregulation in cancer
38. kip1
39. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
40. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
41. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
42. RhoA stimulates p27 Kip degradation through its regulation of cyclin E/Cdk2 activity
43. Kip1
44. Cyclin E-CDK2 is a regulator of p27Kip1
45. New functional activities for the p21 family of cdk inhibitors
46. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
47. Growth inhibition by TGF-β1 linked to suppression of retinoblastoma protein phosphorylation
48. Transforming growth factor β1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest
49. Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression
50. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
51. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta-1
52. Differential modulation of cyclin gene expression by MYC
53. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: Demonstration of a novel role for c-myc
54. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15
55. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway
56. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependant protein kinases
57. Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex
58. Transforming growth factor-β1 inhibits cyclin D1 expression in intestinal epithelial cells
59. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21Cip1 and p27Kip1
60. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β
61. INK4B-cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells
62. p15INK4B is a potential effector of TGF-β induced cell cycle arrest
63. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site
64. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53 independent mechanism
65. waf1 induction are important early events
66. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells
67. Overexpression of the tumor suppressor gene Smad4/DPC4 induces p21 waf1 expression and growth inhibition in human carcinoma cells
68. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B
69. Transforming growth factor beta targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity
70. Cdc25 cell-cycle phosphatase as a target of c-myc
71. Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β
72. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
73. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
74. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
75. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell lymphoblastic leukemia
76. Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression
77. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
78. Kip1 in human malignancies
79. Kip1 gene to 12p13 and its analysis in leukemias
80. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
81. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
82. Decreased levels of the cell cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
83. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells
84. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells
85. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis
86. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma
87. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1
88. Expression and amplification of cyclin genes in human breast cancer
89. Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line
90. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to estrogen receptor status
91. TGF-β inhibition of cdk4 synthesis is linked to cell cycle arrest
92. Gene amplification and overexpression of Cdk4 in sporadic breast carcinomas is associated with high tumor cell proliferation
93. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21 Cip1
94. Direct induction of cyclin D2 by Myc contributes to cell cycle induction and sequestration of p27
95. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc
96. Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones
97. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
98. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
99. Glycogen synthase kinase-3 beta regulates cyclin D1 proteolysis and subcellular localization
100. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent c-erbB-2 gene amplification
101. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F
102. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce responsiveness to a negative growth factor, transforming growth factor β1
103. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes
104. Correlated abnormalities of transforming growth factor-β1 response and p53 expression in thyroid epithelial cell transformation
105. p53-independent role of MDM2 in TGF-beta 1 resistance
106. Abnormal expression of MDM-2 in breast carcinomas
107. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors